Balkan Journal of Medical Genetics

TWIST1 GENE EXPRESSION AS A BIOMARKER FOR PREDICTING PRIMARY DOXORUBICIN RESISTANCE IN BREAST CANCER
Demir S1,10,*, Müslümanoğlu MH2, Müslümanoğlu M3, Başaran S4, Çalay ZZ5, Aydıner A6, Vogt U7, Çakır T8, Kadıoğlu H9, Artan S1
*Corresponding Author: Selma Demir, Ph.D., Trakya University Faculty of Medicine, Department of Medical Genetics, 22030 Iskender, Edirne, Turkey. Tel: +90(284)2357642/2330. Fax: +90(284)2357652. E-mail: selmaulusal@trakya.edu.tr
page: 25

INTRODUCTION

Breast cancer is the most common cancer in women and is also responsible for a great number of cancer-associated deaths among women worldwide [1,2]. Several chemo-therapeutic agents, either alone or in addition to other therapies, are used in the treatment of breast cancer patients. Anthracyclines and taxanes are the most commonly used chemo-therapeutics for breast cancer treatment [3]. Benefit and risk assessment for therapeutic agents for each patient is important because chemotherapy is a conventional method targeting all fast-dividing cells of the organism [4]. Toxicity and primary or secondary resistance are common problems of conventional chemotherapy. Thus, studies focusing on finding biomarkers to predict the response of the patients and tumors to the drugs used are an important part of precision medicine [5]. The twist transcription factor, encoded by the TWIST1 gene (TWIST1; OMIM* 601622) is a member of the basic helix loop helix transcription factor family and has an important role in cell lineage determination and differentiation as an essential regulator during embryogenesis, particularly in mesoderm formation, specification, and differentiation. Pathogenic variations of the TWIST1 gene leads to Saethre-Chotzen syndrome (#101400), Craniosynostosis 1 (#123100), Robinow-Sorauf syndrome (#180750) and Sweeney-Cox syndrome (#617746) in humans [6]. Some studies have extensively demonstrated that the twist transcription is implicated initiation [7], stemness [8], angiogenesis [9] and chemo-resistance in some types of carcinomas, sarcomas and hematological malignancies [10,11]. Induced twist overexpression has been shown to be related to chemo-resistance of breast tumor cells in a study performed on breast tumor cell lines [10]. Twist overexpression has been shown to be related to clinicopathological features of tumors and reported to be a candidate biomarker of shorter overall survival [12]. In this study, we aimed to investigate the relationship between intrinsic TWIST transcription factor expression and the effectiveness of doxorubicin treatment on primary tumor samples directly taken from different chemotherapynaive breast cancer patients. As far as we know, there are no studies investigating the association of the TWIST gene expression differences in primary breast tumor samples taken from patients and their primary sensitivity to doxorubicin.

Number 27 VOL. 27 (2), 2024	Number 27 VOL. 27 (1), 2024
Number 26 Number 26 VOL. 26(2), 2023 All in one	Number 26 VOL. 26(2), 2023
Number 26 VOL. 26, 2023 Supplement	Number 26 VOL. 26(1), 2023
Number 25 VOL. 25(2), 2022	Number 25 VOL. 25 (1), 2022
Number 24 VOL. 24(2), 2021	Number 24 VOL. 24(1), 2021
Number 23 VOL. 23(2), 2020	Number 22 VOL. 22(2), 2019
Number 22 VOL. 22(1), 2019	Number 22 VOL. 22, 2019 Supplement
Number 21 VOL. 21(2), 2018	Number 21 VOL. 21 (1), 2018
Number 21 VOL. 21, 2018 Supplement	Number 20 VOL. 20 (2), 2017
Number 20 VOL. 20 (1), 2017	Number 19 VOL. 19 (2), 2016
Number 19 VOL. 19 (1), 2016	Number 18 VOL. 18 (2), 2015
Number 18 VOL. 18 (1), 2015	Number 17 VOL. 17 (2), 2014
Number 17 VOL. 17 (1), 2014	Number 16 VOL. 16 (2), 2013
Number 16 VOL. 16 (1), 2013	Number 15 VOL. 15 (2), 2012
Number 15 VOL. 15, 2012 Supplement	Number 15 Vol. 15 (1), 2012
Number 14 14 - Vol. 14 (2), 2011	Number 14 The 9th Balkan Congress of Medical Genetics
Number 14 14 - Vol. 14 (1), 2011	Number 13 Vol. 13 (2), 2010
Number 13 Vol.13 (1), 2010	Number 12 Vol.12 (2), 2009
Number 12 Vol.12 (1), 2009	Number 11 Vol.11 (2),2008
Number 11 Vol.11 (1),2008	Number 10 Vol.10 (2), 2007
Number 10 10 (1),2007	Number 9 1&2, 2006
Number 9 3&4, 2006	Number 8 1&2, 2005
Number 8 3&4, 2004	Number 7 1&2, 2004
Number 6 3&4, 2003	Number 6 1&2, 2003
Number 5 3&4, 2002	Number 5 1&2, 2002
Number 4 Vol.3 (4), 2000	Number 4 Vol.2 (4), 1999
Number 4 Vol.1 (4), 1998	Number 4 3&4, 2001
Number 4 1&2, 2001	Number 3 Vol.3 (3), 2000
Number 3 Vol.2 (3), 1999	Number 3 Vol.1 (3), 1998
Number 2 Vol.3(2), 2000	Number 2 Vol.1 (2), 1998
Number 2 Vol.2 (2), 1999	Number 1 Vol.3 (1), 2000
Number 1 Vol.2 (1), 1999	Number 1 Vol.1 (1), 1998

About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact